Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's Disease dementia

Journal of Alzheimer's Disease

Volumn 44, Issue 3, 2015, Pages 897-906

  Claxton, Amy ^a,b   Baker, Laura D ^b   Hanson, Angela ^a,b   Trittschuh, Emily H ^a,b   Cholerton, Brenna ^b   Morgan, Amy ^a,b   Callaghan, Maureen ^a,b   Arbuckle, Matthew ^d   Behl, Colin ^a,b   Craft, Suzanne ^c  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; clinical trials; insulin; intranasal drug administration; mild cognitive impairment; randomized

Indexed keywords

APOLIPOPROTEIN E; INSULIN DETEMIR; LONG ACTING INSULIN; PLACEBO; ANTIDIABETIC AGENT; APOLIPOPROTEIN E4; INSULIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED STUDY; DEMENTIA; DEPTH PERCEPTION; DIZZINESS; DRUG DELIVERY DEVICE; DRUG EFFECT; EXECUTIVE FUNCTION; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TREATMENT OUTCOME; WORKING MEMORY; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENETICS; GLUCOSE TOLERANCE TEST; INTRANASAL DRUG ADMINISTRATION; LONGITUDINAL STUDY; MALE; MENTAL HEALTH; METABOLISM; NEUROPSYCHOLOGICAL TEST; PSYCHOMOTOR DISORDERS; SHORT TERM MEMORY; TIME;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; APOLIPOPROTEIN E4; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; LONGITUDINAL STUDIES; MALE; MEMORY, SHORT-TERM; MENTAL STATUS SCHEDULE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922666525     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141791     Document Type: Article

References (49)

1. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. J Alzheimers Dis 8, 247-268.
2. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21, 2561-2570.
3. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurol 3, 169-178.
4. Craft S, Peskind E, SchwartzMW, Schellenberg GD, Raskind M, Porte D, Jr. (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168.
5. Tomiyama T (2010) [Involvement of beta-amyloid in the etiology of Alzheimer's disease]. Brain Nerve 62, 691-699.
6. Lee CC, Kuo YM, Huang CC, Hsu KS (2009) Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Neurobiol Aging 30, 377-387.
7. de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2, 1101-1113.
8. de la MonteSM(2012) Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 9, 35-66.
9. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338.
10. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG (2012) An antidiabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 122, 1339-1353.
11. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH, 2nd, Craft S (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13, 323-331.
12. Reger MA,Watson GS, Green PS,Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440-448.
13. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol. 69, 29-38.
14. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van DuijnCM(1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. Ameta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349-1356.
15. Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, Plymate S, Latendresse S, Petrova A, Raskind M, Peskind E, Lofgreen C, Grimwood K (1999) Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70, 146-152.
16. Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA, Martins RN, Raskind M, Peskind E, Plymate S (2000) Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci. 903, 222-228.
17. Aisen PS, Berg JD, Craft S, Peskind ER, Sano M, Teri L, Mulnard RA, Thomas RG, Thal LJ (2003) Steroid-induced elevation of glucose in Alzheimer's disease: Relationship to gender, apolipoprotein E genotype and cognition. Psychoneuroendocrinology 28, 113-120.
18. Craft S, Peskind E, SchwartzMW, Schellenberg GD, Raskind M, Porte D, Jr. (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168.
19. Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, Cholerton B, Plymate SR, Arbuckle M, Craft S (2013) Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J Alzheimers Dis 35, 789-797.
20. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD, Krohn AJ (2003) Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: Interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28, 809-822.
21. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 101, 284-289.
22. Kurtzhals P (2004) Engineering predictability and protraction in a basal insulin analogue: The pharmacology of insulin detemir. Int J Obes Relat Metab Disord 28, S23-28.
23. De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW (2005) Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12months in comparison to NPH insulin. Diabetes Obes Metab 7, 73-82.
24. Shen DD, Artru AA, AdkisonKK(2004) Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56, 1825-1857.
25. Tschritter O, Hennige AM, Preissl H, Porubska K, Schafer SA, Lutzenberger W, Machicao F, Birbaumer N, Fritsche A, HaringHU(2007) Cerebrocortical beta activity in overweight humans responds to insulin detemir. PLoS One 2, e1196.
26. BanksWA,Morley JE, Lynch JL, Lynch KM,Mooradian AD (2010) Insulin detemir is not transported across the bloodbrain barrier. Peptides 31, 2284-2288.
27. Monami M, Marchionni N, Mannucci E (2009) Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 11, 372-378.
28. Hennige AM, Sartorius T, Tschritter O, Preissl H, Fritsche A, Ruth P, HaringHU(2006) Tissue selectivity of insulin detemir action in vivo. Diabetologia 49, 1274-1282.
29. Hallschmid M, Jauch-Chara K, Korn O, Molle M, Rasch B, Born J, Schultes B, Kern W (2010) Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes 59, 1101-1107.
30. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29, 1269-1274.
31. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Ivnik RJ, Tangalos EG, Petersen RC, Rocca WA (2008) The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30, 58-69.
32. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
33. Coen RF, Kinsella A, Lambe R, Kenny M, Darragh A (2004) Creating equivalent word lists for the Buschke Selective Reminding Test. Hum Psychopharmacol Clin Exp 5, 47-51.
34. Brickman AM, SternY, Small SA (2011) Hippocampal subregions differentially associate with standardized memory tests. Hippocampus 21, 923-928.
35. Clark CM, Ewbank DC (1996) Performance of the dementia severity rating scale: A caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord 10, 31-39.
36. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,TurnerRC(1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419.
37. Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL, Born J, KernW(2007) Intranasal insulin improves memory in humans: Superiority of insulin aspart. Neuropsychopharmacology 32, 239-243.
38. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53, 1743-1753.
39. Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T (2008) Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract 81, 269-277.
40. Prajapati KD, Sharma SS, Roy N (2012) Hepatocyte nuclear factor-1alpha mediated upregulation of albumin expression in focal ischemic rat brain. Neurol Res 34, 25-31.
41. Ramos-Fernandez E, Tajes M, Palomer E, Ill-Raga G, Bosch-Morato M, Guivernau B, Roman-Degano I, Eraso-Pichot A, Alcolea D, Fortea J, Nunez L, Paez A, Alameda F, Fernandez-Busquets X, Lleo A, Elosua R, Boada M,Valverde MA, Munoz FJ (2014) Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: Implications in cytotoxicity and amyloid-beta peptide aggregation. J Alzheimers Dis 40, 643-657.
42. Colton CA, Needham LK, Brown C, Cook D, Rasheed K, Burke JR, Strittmatter WJ, Schmechel DE, Vitek MP (2004) APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J Neuroimmunol 147, 62-67.
43. Gundry RL, Fu Q, Jelinek CA, Van Eyk JE, Cotter RJ (2007) Investigation of an albumin-enriched fraction of human serum and its albuminome. Proteomics Clin Appl. 1, 73-88.
44. Cao W, Ning J, Yang X, Liu Z (2011) Excess exposure to insulin is the primary cause of insulin resistance and its associated atherosclerosis. Curr Mol Pharmacol 4, 154-166.
45. Cao W, Liu HY, Hong T, Liu Z (2010) Excess exposure to insulin may be the primary cause of insulin resistance. Am J Physiol Endocrinol Metab 298, E372.
46. Mensenkamp AR, Havekes LM, Romijn JA,Kuipers F (2001) Hepatic steatosis and very low density lipoprotein secretion: The involvement of apolipoprotein E. J Hepatol 35, 816-822.
47. Langner R, Sternkopf MA, Kellermann TS, Grefkes C, Kurth F, Schneider F, Zilles K, Eickhoff SB (2014) Translating working memory into action: Behavioral and neural evidence for using motor representations in encoding visuo-spatial sequences. Hum Brain Mapp 35, 3465-3484.
48. Helkala EL, Laulumaa V, Soininen H, Riekkinen PJ (1988) Recall and recognition memory in patients with Alzheimer's and Parkinson's diseases. Ann Neurol 24, 214-217.
49. Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, Pilotto A, Solfrizzi V (2010) Bapineuzumab: Anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy 2, 767-782.